Depression in women

Why rates are higher

The two-to-one ratio is not explained by any single factor. Contributors that the literature consistently identifies:

• Hormonal transitions (puberty, premenstrual, perinatal, perimenopausal) coincide with the windows of highest incidence. The mechanism is not fully understood, but the pattern is consistent across studies.
• Stress exposure is, on average, higher in women across several measured domains: caregiving load, intimate partner violence, sexual assault history, and financial precarity.
• Help-seeking is higher in women, which probably raises diagnosis rates rather than lowering them. Some of the gap may reflect women being more likely to be identified rather than more likely to be ill.
• Symptom presentation in women more often matches the textbook DSM picture (sadness, tearfulness, low mood), which is more readily recognized as depression by clinicians and the patient.

The two-to-one ratio appears across cultures and across most measured income levels. It begins at puberty and narrows in older age.

Premenstrual dysphoric disorder (PMDD)

PMDD is a DSM-5-TR diagnosis defined by mood symptoms (depression, anxiety, irritability, mood swings) that occur in the week before menses, improve within a few days of menses, and become minimal or absent in the week after menses. The pattern repeats across most cycles for at least a year. About 3 to 8 percent of women of reproductive age meet criteria.

PMDD is distinct from premenstrual syndrome (PMS), which is more common and less severe. PMDD requires a prospective two-month symptom diary to confirm the cyclic pattern, since recall alone often does not match the actual pattern.

Treatment options include SSRIs (taken either continuously or only in the luteal phase), combined oral contraceptives (with drospirenone), and, in some cases, GnRH agonists for severe and treatment-resistant PMDD. Cognitive behavioral therapy adapted for PMDD has evidence as a first-line option.

Perinatal depression

Perinatal depression includes depressive episodes that begin during pregnancy (antenatal depression) or in the first year postpartum. About 1 in 7 birthing parents meets criteria. The DSM-5-TR peripartum specifier covers episodes that begin during pregnancy or within four weeks of delivery; in clinical practice, ACOG and most clinicians screen and treat through the first postpartum year.

Screening tools: the Edinburgh Postnatal Depression Scale (EPDS) is the most widely used. ACOG recommends screening at least once during the perinatal period; many practices screen at every prenatal visit and at well-child visits during the first postpartum year.

Treatment: psychotherapy (CBT and IPT have the strongest evidence in this group), antidepressants (sertraline has the most reassuring data in pregnancy and lactation), and the newer agents brexanolone and zuranolone for postpartum-onset depression specifically. The decision to use medication in pregnancy or while breastfeeding is individual and balances the risks of treatment against the well-documented risks of untreated depression.

For full coverage, see Postpartum depression.

Perimenopausal depression

The menopausal transition (typically late 40s to early 50s) is a window of elevated risk. Women with no prior history of depression have about a two-fold increased risk of a first depressive episode during this transition. Women with a prior history are at higher risk of recurrence.

The presentation often includes mood symptoms intertwined with vasomotor symptoms (hot flashes, night sweats), sleep disruption, and cognitive complaints. The combined effect on quality of life is substantial.

Treatment options include standard antidepressants (SSRIs and SNRIs, several of which also reduce vasomotor symptoms), hormone therapy in selected patients, and structured psychotherapy. The decision is individual and accounts for vasomotor severity, sleep disruption, prior depression history, and personal preference.

Treatment considerations across the lifecycle

• Contraception and SSRIs have no major interaction. Some interactions exist with other psychotropics; check with the prescriber.
• Pregnancy planning is a reason to talk to a prescriber before stopping medication, not to stop on your own. Untreated depression carries its own risks for the pregnancy and the postpartum period.
• Lactation compatibility varies by medication. Sertraline and paroxetine have the most reassuring data. LactMed (NIH) is the standard reference.
• Bone health matters with long-term SSRI use after menopause. SSRIs are associated with a small increase in fracture risk, partly through fall risk and partly through direct bone effects. The clinical message is to maintain calcium, vitamin D, weight-bearing exercise, and routine bone density screening as recommended.